
Nephrologist

No OPD information available
Glomerulonephritis
Peritonitis
Secondary Peritonitis
Chronic Kidney Disease
Lupus Nephritis
Systemic Lupus Erythematosus (SLE)
Vasculitis
Calciphylaxis
Cronkhite-Canada Disease
End-Stage Renal Disease (ESRD)
Focal Segmental Glomerulosclerosis
IgA Nephropathy
Interstitial Nephritis
Kidney Transplant
Nephrotic Syndrome
Purpura
Squamous Cell Skin Carcinoma
Thrombocytopenia
Vitamin D Deficiency
Dwarakanathan Ranganathan is a doctor who helps people with kidney and immune system problems. Some of the conditions he treats are Glomerulonephritis, Chronic Kidney Disease, Lupus Nephritis, and Kidney Transplant. He also works with diseases like Peritonitis, Vasculitis, and Thrombocytopenia.
Dr. Ranganathan uses special skills and treatments to care for his patients. He is good at communicating with them, which helps build trust. Patients feel safe and supported under his care.
To stay updated, Dr. Ranganathan reads the latest medical research and attends conferences. This helps him provide the best care based on new information.
Dr. Ranganathan works well with other medical professionals. He shares knowledge and collaborates to give patients the best treatment possible. His positive relationships with colleagues benefit his patients.
Dr. Ranganathan's work has made a big impact on many patients' lives. For example, his research on lupus nephritis led to a new therapy that helped a patient. He is also involved in a clinical trial to find better treatments for glomerular diseases.
One of his notable publications talks about using a special therapy to treat lupus nephritis. This shows his dedication to finding new and better ways to help his patients.
In summary, Dwarakanathan Ranganathan is a caring and skilled doctor who works hard to improve the health and lives of his patients. Through his expertise, communication, and commitment to staying updated, he continues to make a positive impact in the medical field.
Enrollment Status: Active not recruiting
Published: January 30, 2025
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 2
